An experience can change while the labeled amount stays the same. Understanding that difference requires separating what a product contains, what reaches the body and what a person notices.
Imagine a public review that says: “The amount was the same, but this one felt much stronger.” It sounds like a direct comparison of products. Yet the statement reports an experience and a nominal amount; it does not establish chemical content, exposure or the cause of the difference. The experience may be entirely sincere. The analytical conclusion still needs evidence of its own.
The difficulty begins with “stronger.” That word might mean a more noticeable sensation, a larger change in a measured outcome, more active substance in the sample or greater biological activity. Those meanings can overlap, but they are not interchangeable. A useful assessment starts by naming the quantity being compared.
Four quantities hidden inside one comparison
A labeled amount is a stated quantity. An assayed amount is a laboratory result for a defined substance in a particular sample. Systemic exposure describes how much of an active substance reaches the circulation and how its concentration changes over time. Response is the outcome being observed: for example, a symptom rating or a specified physiological measurement. FDA's explanation of bioavailability explicitly distinguishes absorbed drug and its concentration over time from the administered product.[1]
| Quantity | What it describes | Evidence needed |
|---|---|---|
| Labeled amount | Stated content | Product documentation |
| Assayed content | Measured substance | Suitable chemical assay |
| Exposure | Concentration over time | Relevant exposure study |
| Response | Defined outcome | Appropriate outcome data |
These are different measurement questions, rather than four grades of the same test. An assay does not become a human exposure study because it produces a precise number. A convincing account of symptom relief does not become a content assay because the person reports it confidently.
“Potency” also needs a definition. In pharmacology, it can refer to the amount or concentration needed to produce a specified effect. In casual product reviews, people often use it to mean how much active material is present. A claim that does not specify which meaning it uses is difficult to evaluate, even before examining its evidence.
Bioavailability explains why amount is not exposure
FDA's April 2022 guidance recap defines bioavailability as the rate and extent to which an active ingredient is absorbed and becomes available at its site of action. It describes data on systemic absorption, concentration over time and whether exposure increases proportionally with the amount administered.[1] Those are measured relationships, not conclusions available from a product label alone.
The recap also explains why formulation and study context matter. Different dosage forms can require different approaches, and food can affect bioavailability measurements for orally administered products. The guidance concerns studies supporting new drug applications or investigational new drug applications; its principles primarily address oral products and can also apply to some nonoral products assessed through systemic exposure.[1]
This does not establish that a formulation difference caused any particular reviewer's experience. It shows why matching nominal amounts cannot settle the exposure question. Nor does the recap authorize treating two products as bioequivalent because they feel similar. Comparative exposure and regulatory questions require evidence designed for the products and purpose concerned. The source provides scientific context, not a method for adjusting personal use.
A response needs an outcome and a time frame
“Different effect” becomes more informative when the report identifies what changed and when. A pain rating, a laboratory value and a general impression of energy are different outcomes. Even a numerical score needs a defined scale and timing before two observations can be meaningfully compared.
Consider the original hypothetical review. Did “stronger” mean a larger desired effect, a more noticeable unwanted sensation or a longer-lasting impression? Were the comparisons made at comparable times? Were other treatments, ordinary daily conditions or expectations different? These are possible explanatory questions, not diagnoses of the reviewer or established causes of that report.
The distinction protects the value of experience. A symptom report can matter without identifying its mechanism. Concluding “the content must be different” adds a causal claim that the report alone cannot resolve. Concluding “it must all be expectation” makes the same mistake in the opposite direction.
What an expectation experiment actually demonstrated
Bingel and colleagues studied healthy volunteers in a controlled, within-subject experiment published in 2011. They examined the analgesic effect of a fixed concentration of remifentanil, an opioid, during constant heat pain. Conditions differed in expectation: no expectation of analgesia, positive expectation and negative expectation.[2] This was a study of a specific drug and pain task, not a comparison of research-material suppliers.
Positive expectation substantially enhanced the reported analgesic benefit, which the authors described as doubled. Negative expectation abolished the analgesic benefit in that experimental setting. Functional magnetic resonance imaging also showed changes in brain regions involved in coding pain intensity, supporting the reported effects.[2]
The finding demonstrates that, in this controlled context, changing expectation changed the observed benefit while drug concentration was fixed. It does not establish the size of an expectation effect for another substance, outcome or person. It provides no evidence that a particular product was correctly labeled or chemically stable. Crucially, it does not make the volunteers' pain imaginary: the study examined changes in experienced pain and accompanying brain activity.
What a chemical assay can establish
If the disputed claim concerns content, the relevant evidence is an analytical measurement suited to that claim. Eurachem's 2025 method-validation guide describes selectivity as the ability to determine particular analytes in a mixture or matrix without interference. It explains that an instrument commonly measures a property associated with the analyte, so the laboratory must establish that other components do not produce a misleading signal.[3]
Calibration connects instrument response to the quantity being reported. Method performance also involves matters such as precision and bias, while measurement uncertainty belongs to the resulting measurement. The guide treats the calibration function as integral to a quantitative method and uncertainty as a crucial part of a measurement result.[3]
Together, these concepts explain why “a test was done” is incomplete evidence. A reader needs to know what was measured, whether the method suits that substance and sample, and what limitations accompany the result. Even a well-supported content result remains a finding about the analyzed material. It does not independently establish a human effect, clinical equivalence or suitability for consumption. No Chudik testing or method validation is being claimed here.
Reading a stronger-or-weaker claim fairly
A proposed way to assess a public comparison is to separate its observation from its explanation. Record what the person actually reports, identify the exact material and outcome, then examine any product-specific analytical or clinical evidence offered for the proposed cause. Missing information should remain missing; it should not be filled with an assumption of defective material, deception or expectation alone.
A noticeable difference can justify a more careful question. It cannot determine chemical content through sensation. Research-use materials should not be consumed or self-administered, and an anecdotal comparison does not bridge the gap between a laboratory reagent and a clinically evaluated medicine.
This article draws on FDA's bioavailability guidance recap, the original published abstract of Bingel and colleagues' study, and selected sections of the third-edition Eurachem guide. The complete FDA guidance and Bingel paper were not reviewed. These sources explain distinct kinds of evidence; none tests the hypothetical products described here.